Alexion Pharmaceuticals Inc ALXN:NASDAQ

Last Price$123.04NASDAQ Closing Price as of 4:00PM ET 7/15/19
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change+2.22(1.84%)
Bid (Size)$122.58 (1)
Ask (Size)$124.99 (1)
Day Low / High$120.59 - 123.16
Volume929.0 K
 

View Biotechnology IndustryPeer Comparison as of 07/15/2019

 

Alexion Pharmaceuticals Inc ( NASDAQ )

Price: $123.04
Change: +2.22 (1.84%)
Volume: 929.0 K
4:00PM ET 7/15/2019
 
 

Regeneron Pharmaceuticals Inc ( NASDAQ )

Price: $298.20
Change: +5.64 (1.93%)
Volume: 847.5 K
4:00PM ET 7/15/2019
 
 

Agilent Technologies Inc ( NYSE )

Price: $70.55
Change: -1.10 (1.54%)
Volume: 4.0 M
4:01PM ET 7/15/2019
 
 

Incyte Corp ( NASDAQ )

Price: $81.39
Change: +1.29 (1.61%)
Volume: 1.1 M
4:00PM ET 7/15/2019
 
 

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $83.99
Change: +1.04 (1.25%)
Volume: 684.0 K
4:00PM ET 7/15/2019
 

Read more news Recent News

Alexion Pharma Gets European Nod for Ultomiris for Adults with Paroxysmal Nocturnal Hemoglobinuria
1:15PM ET 7/03/2019 MT Newswires

Alexion Pharmaceuticals (ALXN) said on Wednesday the European Commission has approved ULTOMIRIS to treat adult patients with paroxysmal nocturnal...

Insider Trends: 90-Day Insider Selling Trend Prolonged at Alexion Pharmaceuticals
4:52PM ET 7/02/2019 MT Newswires

Indrani Lall Franchini, EVP, Chief Compliance Officer, sold 4,500 shares of Alexion Pharmaceuticals (ALXN) on Jul 01, 2019, for $597,510. Following the...

S&P 500 Movers: Western Digital Jumps 4%, Leads Gainers; McCormick Slips 2%
11:59AM ET 6/28/2019 MT Newswires

S&P 500 Top % Movers as of 11:55 am ET Gainers WDC, +4.2% CAG, +4.1% ALXN, +2.9% FL, +2.9% BAC, +2.8% Losers MKC, -2.3% ROL, -2.1% UNH, -1.5% ...

Alexion Pharmaceuticals Gets FDA Nod for Soliris for Autoimmune Disease, Stock Rises
2:54PM ET 6/27/2019 MT Newswires

Alexion Pharmaceuticals (ALXN) said on Thursday the US Food and Drug Administration has approved Soliris for the treatment of neuromyelitis optica spectrum...

View all Commentary and Analysis

Alexion Might Finally Satisfy The Market
7:06AM ET 7/08/2019 Seeking Alpha

Alexion: A Good Buy For Long-Term Appreciation
7:04AM ET 7/04/2019 Seeking Alpha

Nike, FedEx And Bank Stress Tests (Stocks To Watch Podcast)
7:35AM ET 6/23/2019 Seeking Alpha

Stocks To Watch: Nike, FedEx And Bank Stress Tests
7:37AM ET 6/22/2019 Seeking Alpha

Company Profile

Business DescriptionAlexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA. View company web site for more details
Address121 Seaport Boulevard
Boston, Massachusetts 02210
Phone+1.475.230.2596
Number of Employees2,656
Recent SEC Filing07/02/20194
Chief Executive Officer & DirectorLudwig N. Hantson
Chief Financial Officer & Executive Vice PresidentPaul J. Clancy
Executive VP, Head-Research & DevelopmentJohn J. Orloff
Chief Compliance Officer & Executive VPIndrani M. Franchini

Company Highlights

Price Open$120.72
Previous Close$120.82
52 Week Range$92.56 - 141.86
Market Capitalization$27.6 B
Shares Outstanding224.2 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement07/24/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings66.02
Earnings per Share$5.78
Beta vs. S&P 500N/A
Revenue$4.1 B
Net Profit Margin9.63%
Return on Equity4.52%

Analyst Ratings as of 07/05/2019

Buy
12
Overweight
3
Hold
4
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset